Unknown PHASE4 INTERVENTIONAL 2-arm NCT02237937

Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene

Sponsor: HolsboerMaschmeyer NeuroChemie GmbH

Interventions Amitriptyline Amitriptylinoxide Citalopram Escitalopram Nortriptyline Paroxetine Sertraline Trimipramine Venlafaxine

Updated 5 times since 2017 Last updated: Sep 9, 2014 Started: Sep 30, 2011 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Major Depression and is currently ongoing. HolsboerMaschmeyer NeuroChemie GmbH leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HolsboerMaschmeyer NeuroChemie GmbH
Max-Planck-Institute of Psychiatry

Data source: HolsboerMaschmeyer NeuroChemie GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany